SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 1, 2014, Pages 36-45

  Zhang, Hao Tian ^a   Wang, Lu ^b   Ai, Jing ^b   Chen, Yi ^b   He, Chang Xi ^b   Ji, Yin Chun ^b   Huang, Min ^b   Yang, Jing Yu ^a   Zhang, Ao ^b   Ding, Jian ^b   Geng, Mei Yu ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPIPERAZIN 1 YL) 5 (3 NITROBENZYLAMINO) 7 (TRIFLUOROMETHYL)QUINOLINE; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; INTERLEUKIN 8; KI 67 ANTIGEN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMG 833; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE FUSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; MET GENE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-8; MICE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84903527461     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214817     Document Type: Article

References (39)

1. Abounader R and Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol 7:436-451. (Pubitemid 41555616
2. Bendell JC, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, and Hack SP (2013) Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 12:218-222.
3. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, and Lockhart BP, et al. (2009) Only a subset of Metactivated pathways are required to sustain oncogene addiction. Sci Signal 2:er11.
4. Birchmeier C, Birchmeier W, Gherardi E, and Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925. (Pubitemid 37493640
5. Boccaccio C and Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637-645. (Pubitemid 44140861
6. Broekman F, Giovannetti E, and Peters GJ (2011) Tyrosine kinase inhibitors: multitargeted or single-targeted? World J Clin Oncol 2:80-93.
7. Comoglio PM, Giordano S, and Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516. (Pubitemid 351767118
8. Comoglio PM and Trusolino L (2002) Invasive growth: from development to metastasis. J Clin Invest 109:857-862. (Pubitemid 34275105
9. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, and Vande Woude GF (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29-33. (Pubitemid 14065275
10. Dietel M and Sers C (2006) Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 448:744-755. (Pubitemid 43824431
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, and Christensen J, et al. (2007)MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. (Pubitemid 46799492
12. Gherardi E, Birchmeier W, Birchmeier C, and Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89-103.
13. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, and Rosen EM (1993) Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90:1937-1941. (Pubitemid 23069972
14. He CX, Ai J, Xing WQ, Chen Y, Zhang HT, Huang M, Hu YH, Ding J, and Geng MY (2014) Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Metdependent neoplastic phenotypes of human cancer cells. Acta Pharmacol Sin 35:89-97.
15. Hill KS, Gaziova I, Harrigal L, Guerra YA, Qiu S, Sastry SK, Arumugam T, Logsdon CD, and Elferink LA (2012) Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS ONE 7:e40420.
16. Hood L and Friend SH (2011) Predictive, personalized, preventive, participatory (P4) cancer medicine. Nature Rev Clin Oncol 8:184-187.
17. Jeffers M, Rong S, and Vande Woude GF (1996a) Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16:1115-1125. (Pubitemid 26061683
18. Jeffers M, Rong S, and Vande Woude GF (1996b) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl) 74:505-513. (Pubitemid 26306792
19. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, and Ngo V, et al. (2012) Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 18:1118-1122.
20. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, and Quesnelle KM, et al. (2009) HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 15:3740-3750.
21. Lemmon MA and Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
22. Li A, Dubey S, Varney ML, Dave BJ, and Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170:3369-3376. (Pubitemid 36302216
23. Ma PC (2012) Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 79 (Suppl 1):eS56-60.
24. Montesano R, Matsumoto K, Nakamura T, and Orci L (1991) Identification of a fibroblastderived epithelial morphogen as hepatocyte growth factor. Cell 67:901-908. (Pubitemid 121001504
25. Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen YX, Huang X, Chan HM, and Zhao P, et al. (2005) Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 11:6190-6197. (Pubitemid 41262947
26. Sequist LV, von Pawel J, Garmey EG, Akerley WL, BruggerW, Ferrari D, Chen Y, Costa DB, Gerber DE, and Orlov S, et al. (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307-3315.
27. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, and Frederick DT, et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-504.
28. Torti D, Sassi F, Galimi F, Gastaldi S, Perera T, Comoglio PM, Trusolino L, and Bertotti A (2012) A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer 130:1357-1366.
29. Trusolino L, Bertotti A, and Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848.
30. Trusolino L and Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2:289-300. (Pubitemid 37328782
31. Wang MH, Wang D, and Chen YQ (2003) Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24:1291-1300. (Pubitemid 37038819
32. Wang Y, Ai J, Wang Y, Chen Y, Wang L, Liu G, Geng M, and Zhang A (2011) Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5- (3-nitrobenzylamino)-7-(trifluoromethyl)quinoline as a novel anticancer agent. J Med Chem 54:2127-2142.
33. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, and Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349. (Pubitemid 30070761
34. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, and Sosman J, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-509.
35. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, and Kuwano M (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17:4015-4023. (Pubitemid 27281877
36. You WK and McDonald DM (2008) The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 41:833-839.
37. Zhang YW, Su Y, Volpert OV, and Vande Woude GF (2003) Hepatocyte growth factor/ scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100:12718-12723. (Pubitemid 37339965
38. Zhang YW and Vande Woude GF (2003) HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408-417.
39. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, and Kung PP, et al. (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408-4417. (Pubitemid 46815090)